Observational study of the characteristics of clinical and brain imaging findings, including cognitive function, and the risk of dementia at memory clinics.

Observational study on the characteristics of clinical and brain imaging findings and the risk of dementia. - Observational study on the characteristics of clinical and brain imaging findings and the risk of dementia.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000057200

Enrollment

4000

Registered

2025-03-04

Start date

2018-02-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

dementia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who visited the Memory Clinic of Keio University Hospital, the Department of Psychiatry and Neurology and the Department of Neurology between January 2008 and 31 May 2035 and underwent head MRI, SPECT, amyloid PET, tau PET, neuropsychological testing, blood test apoE gene testing and clinical symptom assessment during the course of their regular medical care. In addition to the above, the already completed studies Investigation of the risk of developing Alzheimer disease by FDG-PET and amyloid imaging in patients undergoing physical examination (approval number 20140388) and Alzheimer's disease by FDG-PET in patients undergoing physical examination. Establishment of a pre-onset diagnosis method (approval number 20120099), and Investigation of amyloid imaging in patients with Parkinson's disease (approval number 20140020).

Exclusion criteria

Exclusion criteria: If a research collaborator expresses a refusal, he or she is excluded from the study.

Design outcomes

Primary

Measure	Time frame
1)Clinical symptoms The following scale is used at the Keio University Hospital Memory Clinic and the outpatient department of neuropsychiatry. Severity Clinical Dementia Rating Depression Geriatric Depression Scale ADL Barthel index Troublesome Behaviour Scale Neuropsychiatric Inventory (NPI) Stroke Scale Hachinski Ischemic Score Caregiver burden Zarit Caregiver Burden 2)Cognitive function The neuropsychological tests conducted as screening tests at the Memory Clinic and the Department of Neuropsychiatry at Keio University Hospital are as follows Brief Dementia Test MMSE and Crock Drawing Test, Cognitive Quotient Test Generalised Intelligence Raven Colour Progressive Matrix Memory (Auditory) Rey Auditory Verbal Learning Test Logical Memory Test Visual Rey-Osterrieth Complex Figure Test Attentional functions Trail Making Test Frontal Lobe Function Revised Stoop Test Word Fluency Test 3)Brain imaging MRI data taken at Keio University Hospital in the usual clinical practice will be used. 4)Cerebral blood flow imaging The results of single photon emission computed tomography (SPECT) 5) Amyloid and tau PET. PET tests that are covered by insurance or have received marketing authorisation. 6) Blood tests. Blood tests that are covered by insurance or have marketing authorisation. 7) apoE gene test APOE genetic test to assess the risk of developing adverse effects when anti-amyloid-beta antibody drugs are introduced.	—

Measure

Time frame

1)Clinical symptoms The following scale is used at the Keio University Hospital Memory Clinic and the outpatient department of neuropsychiatry. Severity Clinical Dementia Rating Depression Geriatric Depression Scale ADL Barthel index Troublesome Behaviour Scale Neuropsychiatric Inventory (NPI) Stroke Scale Hachinski Ischemic Score Caregiver burden Zarit Caregiver Burden 2)Cognitive function The neuropsychological tests conducted as screening tests at the Memory Clinic and the Department of Neuropsychiatry at Keio University Hospital are as follows Brief Dementia Test MMSE and Crock Drawing Test, Cognitive Quotient Test Generalised Intelligence Raven Colour Progressive Matrix Memory (Auditory) Rey Auditory Verbal Learning Test Logical Memory Test Visual Rey-Osterrieth Complex Figure Test Attentional functions Trail Making Test Frontal Lobe Function Revised Stoop Test Word Fluency Test 3)Brain imaging MRI data taken at Keio University Hospital in the usual clinical practice will be used. 4)Cerebral blood flow imaging The results of single photon emission computed tomography (SPECT) 5) Amyloid and tau PET. PET tests that are covered by insurance or have received marketing authorisation. 6) Blood tests. Blood tests that are covered by insurance or have marketing authorisation. 7) apoE gene test APOE genetic test to assess the risk of developing adverse effects when anti-amyloid-beta antibody drugs are introduced.

—

Countries

Japan

Contacts

Public ContactDAISUKE ITO

Keio University School of Medicine Department of Neurology/Memory center

d-ito@jk9.so-net.ne.jp07048333403

Outcome results